Inhibition of Angiogenesis by Small-Molecule Antagonists of Protease-Activated Receptor-1

ABSTRACT

Angiogenesis, the growth of new blood vessels from preexisting ones, is a necessary component of embryogenesis, wound healing, and the proliferative phase of the female reproductive cycle. Angiogenesis also plays a critical role in important pathologic processes such as cancer and cardiovascular complications. In addition, clinical, laboratory, and pharmacologic evidence has shown a link between angiogenesis, coagulation, hemostasis, and thrombosis in the settings of these pathologies. Recent studies in our laboratory revealed that thrombin has a significant stimulatory effect on angiogenesis. This effect of thrombin is independent of fibrin formation and can be attributed mainly to the activation of protease-activated receptor-1 (PAR-1). PAR-1 is widely expressed in vascular cells and is involved in cardiovascular complications such as atherosclerosis, restenosis, and neointimal formation. It is also expressed in many cancer cells contributing to induction of tumor growth and metastasis. In this review, we will summarize our present-day understanding of the role of thrombin and PAR-1 in angiogenesis and the potential therapeutic utility of targeting PAR-1 in angiogenesis-related disease, such as atherosclerosis, restenosis, and cancer.

KEYWORDS

Thrombin - PAR-1 antagonists - angiogenesis - tumor growth - cardiovascular diseases

REFERENCES

• 1 Moser M, Patterson C. Thrombin and vascular development.  Arterioscler Thromb Vasc Biol. 2003;  23 922-930
• 2 Tsopanoglou N E, Pipilli-Synetos E, Maragoudakis M E. Thrombin promotes angiogenesis by a mechanism independent of fibrin-formation.  Am J Physiol. 1993;  264 C1302-C1307
• 3 Haralambopoulos G C, Grant D S, Klienmann H K, Maragoudakis M E. Thrombin promotes endothelial cell alignment in matrigel in vitro and angiogenesis in vivo.  Am J Physiol. 1997;  273 C234-C245
• 4 Ossovskaya V S, Bunnett N W. Protease-activated receptors: contribution to physiology and disease.  Physiol Rev. 2004;  84 579-621
• 5 Vu T-KH, Hung D T, Wheaton V I, Coughlin S R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation.  Cell. 1991;  64 1057-1068
• 6 Kuliopulos A, Civic L, Seeley S K, Sheridan P J, Helin J, Costello C E. Plasmin desensitization of the PAR-1 thrombin receptor: kinetics, sites of truncation and implications for thrombolutic therapy.  Biochemistry. 1999;  38 4572-4585
• 7 Riewald M, Kravchenko V V, Petrovan R J et al.. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1.  Blood. 2001;  97 3109-3116
• 8 Riewald M, Petrovan R J, Donner A, Mueller B M, Ruf W. Activation of endothelial cell protease-activated receptor 1 by the protein C pathway.  Science. 2002;  296 1880-1882
• 9 Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopoulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells.  Cell. 2005;  120 303-313
• 10 Steinhoff M, Buddenkotte J, Shpacovitch V et al.. Proteinase-activated receptors: Transducers of proteinase-mediated signaling in inflammation and immune response.  Endocr Rev. 2005;  26 1-43
• 11 Dvorak H F. Angiogenesis: update 2005.  J Thromb Haemost. 2005;  3 1835-1842
• 12 Rickles F R, Patierno S, Fernandez P M. Tissue factor, thrombin and cancer.  Chest. 2003;  124 58S-68S
• 13 Fernandez P M, Patierno S R, Rickles F R. Tissue factor and fibrin in tumor angiogenesis.  Semin Thromb Hemost. 2004;  30 31-44
• 14 Wojtukiewicz M Z, Sierko E, Rak J. Contribution of the hemostatic system to angiogenesis in cancer.  Semin Thromb Hemost. 2004;  30 5-20
• 15 Tsopanoglou N E, Maragoudakis M E. Role of thrombin in angiogenesis and tumor progression.  Semin Thromb Hemost. 2004;  30 63-69
• 16 Griffin C T, Srinivasa Y, Zheng Y W, Huang W, Coughlin S R. A role for thrombin receptor signaling in endothelial cells during embryonic development.  Science. 2001;  293 1666-1670
• 17 Caunt M, Huang Y, Brooks P, Karpatkin S. Thrombin induces neoangiogenesis in the chick chorioallontoic membrane.  J Thromb Haemost. 2003;  1 2097-2102
• 18 Huang Y-Q, Li J-J, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, Du145 prostate cells and CHRF megakaryocytes.  Thromb Haemost. 2001;  86 1094-1098
• 19 Huang Y-Q, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells.  Blood. 2002;  99 1646-1650
• 20 Tsopanoglou N E, Maragoudakis M E. On the mechanism of thrombin-induced angiogenesis: potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors.  J Biol Chem. 1999;  274 23969-23976
• 21 Zucker S, Conner C, DiMassmo B I et al.. Thrombin induces the activation of progelatinase A in vascular endothelial cells.  J Biol Chem. 1995;  270 23730-23738
• 22 Caunt M, Hu L, Tang T, Brooks P, Ibrahim S, Karpatkin S. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis.  Cancer Res. 2006;  66 4125-4132
• 23 Mohle R, Green D, Moore M, Nachman R, Rafii S. Constitute production and thrombin-induced release of VEGF by human megakaryocytes and platelets.  Proc Natl Acad Sci USA. 1997;  94 663-668
• 24 Li J J, Huang Y Q, Basch R, Karpatkin S. Thrombin induces the release of angiopoietin-1 from platelets.  Thromb Haemost. 2001;  85 204-206
• 25 Ma L, Perini R, McKnight W et al.. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets.  Proc Natl Acad Sci USA. 2005;  102 216-220
• 26 Olivot J-M, Estebanell E, Lafay M, Brohard B, Aiach M, Rendu F. Thrombomodulin prolongs thrombin-induced extracellular signal-regulated kinase phosphorylation and nuclear retention in endothelial cells.  Circ Res. 2001;  88 681-687
• 27 Tsopanoglou N E, Maragoudakis M E. On the mechanism of thrombin-induced angiogenesis: inhibition of attachment of endothelial cells on basement membrane components.  Angiogenesis. 1998;  1 192-200
• 28 Tsopanoglou N E, Adriopoulou P, Maragoudakis M E. On the mechanism of thrombin-induced angiogenesis: involvement of ανβ3 integrin.  Am J Physiol Cell Physiol. 2002;  283 C1501-C1510
• 29 Tsopanoglou N E, Papaconstantinou M, Flordellis C S, Maragoudakis M E. On the mode of action of thrombin-induced angiogenesis: thrombin peptide, TP508, mediates effects in endothelial cells via ανβ3.  Thromb Haemost. 2004;  92 846-857
• 30 Papaconstantinou M E, Carrell C J, Pineda A O et al.. Thrombin functions through its RGD sequence in a non-canonical conformation.  J Biol Chem. 2005;  280 29393-29396
• 31 Nash G F, Walsh D C, Kakkart A K. The role of the coagulation system in tumor angiogenesis.  Lancet Oncol. 2001;  2 608-613
• 32 Prins M, Otten H-MM. Thrombosis and cancer: a short history of Trousseau's syndrome. In: Lugassy G, Falanga A, Kakkar A, Rickles F Thrombosis and Cancer. London, New York; Taylor & Francis 2004: 1-10
• 33 Nierodzik M L, Karpathin S. Thrombin induces tumor growth, metastasis and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype.  Cancer Cell. 2006;  10 355-362
• 34 Hanahan D, Weinberg R A. The hallmarks of cancer.  Cell. 2000;  100 57-70
• 35 Wojtukiewicz M Z, Tang D G, Ben-Joset E, Renaud C, Walz D A, Honn K V. Solid tumor cells express functional “tethered ligand” thrombin receptor.  Cancer Res. 1995;  55 698-704
• 36 Even-Ram S, Uziely B, Cohen P et al.. Thrombin receptor overexpression in malignant and physiological invasion processes.  Nat Med. 1998;  4 909-914
• 37 Whitehead I, Kirk H, Kay R. Expression cloning of oncogenes by retroviral transfer of cDNA libraries.  Mol Cell Biol. 1995;  15 704-710
• 38 Martin C B, Mahon G M, Klinger M B et al.. The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways.  Oncogene. 2001;  20 1953-1963
• 39 Marinissen M J, Servitja J-M, Offermann S, Simon M I, Gutkind J S. Thrombin protease-activated receptor-1 signals through Gq-and G13-initiated MAPK cascade regulating c-Jun expression to induce cell transformation.  J Biol Chem. 2003;  278 46814-46825
• 40 Marinissen M J, Gutkind J S. G-protein-coupled receptors and signaling networks: emerging paradigms.  Trends Pharmacol Sci. 2001;  22 368-376
• 41 Yin Y-J, Salah Z, Maoz M et al.. Oncogenic transformation induces tumor angiogenesis: a role for PAR-1 activation.  FASEB J. 2003;  17 163-174
• 42 Nierodzik M L, Kajumo F, Karpatkin S. Effects of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and metastasis in vivo.  Cancer Res. 1992;  52 3267-3272
• 43 Nierodzik M L, Chen K, Takeshita K et al.. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis.  Blood. 1998;  92 3694-3700
• 44 Fischer E G, Wolfram R, Mueller B M. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells.  Cancer Res. 1995;  55 1629-1632
• 45 Even-Ram S C, Maoz M, Pokroy E et al.. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha v beta 5 integrin.  J Biol Chem. 2001;  276 10952-10962
• 46 Zain J, Huang Y, Feng X S, Nierodzik M L, Li J-J, Karpatkin S. Concentration-dependent dual effects of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells.  Blood. 2000;  95 3133-3138
• 47 Kamath L, Meydani A, Foss F, Kuliopulos A. Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells.  Cancer Res. 2001;  61 5933-5940
• 48 Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells.  Am J Pathol. 2003;  162 1503-1513
• 49 Khurana R, Simons M, Martin J F, Zachary I C. Role of angiogenesis in cardiovascular desease. A critical appraisal.  Circulation. 2005;  112 1813-1824
• 50 Leger A J, Covic L, Kuliopoulos A. Protease-activated receptors in cardiovascular diseases.  Circulation. 2006;  114 1070-1077
• 51 Moulton K S, Heller E, Konerding M A, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.  Circulation. 1999;  99 1726-1732
• 52 Moulton K S, Vakili K, Zurakowski D et al.. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atheroscrerosis.  Proc Natl Acad Sci USA. 2003;  100 4736-4741
• 53 Celletti F L, Waugh J M, Amabile P G, Brendolan A, Hilfiker P R, Dake M D. Vascular endothelial growth factor enhances atheroscrerotic plaque progression.  Nat Med. 2001;  7 425-429
• 54 Shibata M, Susuki H, Nakatami M et al.. The involvement of vascular endothelial growth factor and flt-1 in the process of neontimal proliferation in pig coronary arteries following stent implantation.  Histochem Cell Biol. 2001;  116 471-481
• 55 Edelman E R, Nugent M A, Smith L T, Karnovsky M J. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries.  J Clin Invest. 1992;  89 465-473
• 56 Kwon H M, Sangiorgi G, Ritman E L et al.. Adventitial vasa vasorum in balloon-injured coronary arteries: visualization and quantitation by a microscopic three-dimensional computed tomography technique.  J Am Coll Cardiol. 1998;  32 2072-2079
• 57 Shigematsu K, Yasuhara H, Shigematsu H. Topical application of antiangiogenic agent AGM-1470 suppresses anastomic intimal hyperplasia after ePTFE grafting in a rabbit model.  Surgery. 2001;  129 220-230
• 58 Westerband A, Gentile A T, Hunter G C et al.. Intimal growth and neovascularization in human stenotic vein grafts.  J Am Coll Surg. 2000;  191 264-271
• 59 Pels K, Labinaz M, Hoffert C, O'Brien E R. Adventitial angiogenesis early after coronary angioplasty: correlation with arterial remodeling.  Arterioscler Thromb Vasc Biol. 1999;  19 229-238
• 60 Ohta O, Kusaba A. Development of vasa vasorum in the arterially implanted autovein bypass graft and its anastomosis in the dog.  Int Angiol. 1997;  16 197-203
• 61 Celletti F L, Waugh J M, Amabile P G, Kao E Y, Boroumand S, Dake M D. Inhibition of vascular endorthelial growth factor-mediated neointima progression with angiostatin or paclitaxel.  J Vasc Interv Radiol. 2002;  13 703-707
• 62 Ohtani K, Egashira K, Hiasa K et al.. Blockage of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells.  Circulation. 2004;  110 2444-2452
• 63 Harker L A, Hanson S, Kelly A B. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.  Thromb Haemost. 1997;  78 736-741
• 64 Ruggeri Z M. Platelets in atherothrombosis.  Nat Med. 2002;  8 1227-1234
• 65 Coughlin S R. Protease-activated receptors in hemostasis, thrombosis and vascular biology.  J Thromb Haemost. 2005;  3 1800-1814
• 66 Nelken N A, Soifer S J, O'Keefe J, Vu T K, Charo I F, Coughlin S R. Thrombin receptor expression in normal and atherosclerotic human arteries.  J Clin Invest. 1992;  90 1614-1621
• 67 Takada M, Tanaka H, Yamada T et al.. Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameter after angioplasty in raty.  Circ Res. 1998;  82 980-987
• 68 Cheung W M, D'Andrea M R, Andrade-Gordon P, Damiano B P. Altered vascular injury responses in mice deficient in protease-activated receptor-1.  Arterioscler Thromb Vasc Biol. 1999;  19 3014-3024
• 69 Ahn H-S, Foster C, Boykow G, Stamford A, Manna M, Graziano M. Inhibition of cellular action of thrombin by N3-cuclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (SCH79797), a nonpeptide thrombin receptor antagonist.  Biochem Pharmacol. 2000;  60 1425-1434
• 70 Andrade-Gordon P, Maryanoff B E, Derian C K et al.. Design, synthesis and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor.  Proc Natl Acad Sci USA. 1999;  96 12257-12262
• 71 Zhang H C, Derian C K, Andrade-Gordon P et al.. Discovery and optimization of a novel series of thrombin receptor (PAR-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates.  J Med Chem. 2001;  44 1021-1024
• 72 Andrade-Gordon P, Derian C K, Maryanoff B E et al.. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.  J Pharmacol Exp Ther. 2001;  298 34-42
• 73 Chackalamannil S, Xia Y, Greenlee W J et al.. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents.  J Med Chem. 2005;  48 5884-5887
• 74 Covic L, Gresser A L, Talavera J, Swift S, Kuliopulos A. Actvation and inhibition of G-protein-coupled receptors by cell-penetrating membrane-tethered peptides.  Proc Natl Acad Sci USA. 2002;  99 643-648
• 75 Zania P, Kritikou S, Flordellis C S, Maragoudakis M E, Tsopanoglou N E. Blockage of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis.  J Pharmacol Exp Ther. 2006;  318 246-254